Adc Therapeutics Sa · NYSE:ADCT

Adc Therapeutics Sa — Corporate Update (May 2024)

13 slides from Adc Therapeutics Sa's corporate update, May 6, 2024

  1. Slide 1: ZYNLONTA R/R MZL Phase 2 IIT Initial Data

    May 2024 ZYNLONTA R/R MZL Phase 2 IIT Initial Data Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a re

  3. Slide 3: Key Takeaways – ZYNLONTA R/R MZL Phase 2 IIT Initial Data

    3 Estimated 3 – 4 K 2L+ MZL patients are drug-treated in the US1; despite patients achieving durable responses, high unmet medical need remains with <30% CR for 2L+ NCCN preferred treatments2 Total addressable 2L+ MZL patient population has a potential peak market value of approximately $500 M3; Pot

  4. Slide 4: Overview of MZL Market and ZYNLONTA Study

    4 Overview of MZL Market and ZYNLONTA Study Source: 1. Clarivate DRG (2022), Global Data (2017), Cerner Enviza CancerMPact (2023); 2.NCCN guidelines; 3. MAGNOLIA: ph2, single arm in r/r MZL, AUGMENT: ph3, randomized of R2 vs. R in r/r iNHL, GADOLIN: ph3 randomized of benda vs. benda + obin in r/r iN

  5. Slide 5: Current MZL Treatment Landscape

    5 3L+ Current MZL Treatment Landscape LoT: Line of Therapy. Source: 1. Clarivate DRG (2022), Global Data (2017), Cerner Enviza CancerMPact (2023); 2. NCCN Guidelines. LoT / Epidemiology1 Treatment Paradigm2 Anti-CD20-based regimens BTKis Anti-CD20-based regimens T-cell-mediated therapy (Axi-cel)Anti

  6. Slide 6: Response Rates in Relapsed/Refractory MZL for Current NCCN Preferred Regimens

    6 17% 13% 62% 40% Benda + Obin1* n=46 Acalabrutinib4 n=43 CR PR 26% 29% 42% 36% Zanubrutinib2 n=68 R25 n=63 CR PR NCCN Preferred^, FDA Approved Regimens NCCN Preferred Regimens^ 68% ORR 65% ORR 79% ORR 53% ORR Zanu r tinib2 n 68 24 n 63 Be * + Obin1 n 46 Acalabrutinib3 n 43 Response Rates in Relapse

  7. Slide 7: A Phase 2, Open-label Study Evaluating Loncastuximab in R/R MZL

    7 A Phase 2, Open-label, Study Evaluating Safety and Efficacy of Loncastuximab in R/R MZL Source: 1. UTX-TGR-205 Study (two single-arm cohorts; total n = 710, total MZL n = 69). Clinical Design R/R MZL Previously Treated with ≥ 1 Line of Systemic Therapy Loncastuximab 150 μg / kg (Day 1, +/- 3) CT /

  8. Slide 8: Patient Baseline Characteristics from Initial Data

    8 Patient Baseline Characteristics from Initial Data 15 evaluable patients out of 20 enrolled patients as of 04/18/2024 *Prior lines of treatment included current standard of care including R-based regimens, systemic chemo, BTKis, and CAR-T. NBaseline Characteristics 15Number of patients 64 (48 – 80

  9. Slide 9: Initial Efficacy and Safety Findings

    9 PR CR PD SD Patients on ZYNLONTA treatment Patient stopped treatment Patient stopped due to a toxicity  13 out of 15 patients with a CR, 1 out of 15 with a PR  9 out of 13 CRs were achieved after 2 cycles  All patients achieving responses are maintaining them as of the data cutoff Initial Effic

  10. Slide 10: Advancing ZYNLONTA Development in B-Cell Lymphomas

    10 Proportion of patients by line-of-therapy* DLBCL, FL & MZL account for ~60% of mature B-cell lymphomas1 1L (~70%) 1L (~65%) 1L (~61%) MZL^FLDLBCL Key: Current Approval Current Development Areas Advancing ZYNLONTA Development in B-Cell Lymphomas *Distribution by line of therapy is based on the inc

  11. Slide 11: LOTIS-7 Part 1 Dose Escalation CRS Profile

    11 Arm F* (ZYNLONTA + Mosun) n = 9 Arm E* (ZYNLONTA + Glofit) n = 9 n (%)Grade 4 (44.4%)2 (22%)Grade 1 1 (11%)1 (11%)Grade 2 0 (0%)0 (0%)Grade >3 5 (55.6%)3 (33.3%)Total CRS Profile  After the first investigator assessment, evidence of anti- tumor activity (complete response or partial response) wa

  12. Slide 12: LOTIS-7 Dose Escalation Grade 3/4 Adverse Events

    12 LOTIS 7 Part 1 Dose Escalation Grade 3 and 4 Adverse Events Regardless of relatedness, Data as of April 19, 2024 *A patient may have more than one adverse event Total N=18 Arm F (Lonca + Mosun) N=9 Arm E (Lonca + Glofit) N=9 Patients Treated 18 (100 %) 9 (100 %) 9 (100 %) Patients with any grade

  13. Slide 13: LOTIS-7 Dose Escalation Summary of Serious Adverse Events

    13 LOTIS 7 Part 1 Dose Escalation Summary of Serious Adverse Events Regardless of relatedness, Data as of April 19, 2024 *CRS expressed as number of patients with at least 1 CRS event. 2 patients experienced multiple Grade 1 CRS events. 5 of 8 patients experiencing CRS coded SAE based on whether hos

ADC Therapeutics — Corporate Update (May 2024) on 6ix